Navigation Links
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Date:6/8/2009

"Further, carfilzomib has been generally well tolerated, and the compound's selectivity appears to avoid the off-target effects, such as peripheral neuropathy, associated with currently available proteasome inhibitors."

Adverse events were generally mild and manageable and carfilzomib has been well tolerated for up to one year. Of 31 patients treated, 29 percent have received 12 full cycles of treatment.

These data were reported by Dr. Stewart in an oral presentation, titled "# 0474: Safety and Efficacy Update of PX-171-004, an Open-label Phase II Trial of Carfilzomib in Relapsed Multiple Myeloma," on Saturday, June 6, 2009.

Carfilzomib Combination with Lenalidomide is Well-Tolerated; Achieves Responses in Heavily Pre-treated Patients at Low Doses

Positive preliminary data from an ongoing Phase 1b dose-escalating trial of carfilzomib in combination with lenalidomide and low-dose dexamethasone in relapsed and refractory patients was presented by Michael Wang, M.D., of the University of Texas MD Anderson Cancer Center on Sunday, June 7, 2009. The Phase 1b clinical trial is designed to evaluate safety and to establish a maximum-tolerated dose of carfilzomib in combination with lenalidomide and dexamethasone administered on a 28-day treatment cycle. Lenalidomide in combination with dexamethasone is currently indicated for use in patients with multiple myeloma who have had at least one prior therapy.

To date, the combination of carfilzomib and lenalidomide was well tolerated in heavily pre-treated patients and adverse events were manageable. The most common adverse events reported include anemia and fatigue. No cases of peripheral neuropathy, a common adverse event associated with approved proteasome inhibitors, have been reported. A maximum-tolerated dose has not yet been established and dose-escalation in this trial continues.

Sixty-one percent of the
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
7. Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Materials in Society Lecture Series ... 30 2015   Elsevier , a world-leading ... and publishing home of Materials Today , announced that ... Materials in Society  Lecture Series . The ... International Conference on Materials for Advanced Technologies (ICMAT) ...
(Date:3/31/2015)... , March 31, 2015   Mapi ... integrating Mapi,s Medical Affairs and global Risk Management ... a previously announced acquisition . ... are conducted by a global team that includes ... have decades of experience in navigating complex safety ...
(Date:3/31/2015)... Angeles, CA (PRWEB) March 31, 2015 ... and Professors from the top U.S and International Medical ... share their latest research on the application of stem ... diseases. The symposium is organized and funded by the ... independent nonprofit that has been convening intimate meetings of ...
(Date:3/30/2015)... Francisco, CA (PRWEB) March 30, 2015 ... tax incentives provided you the government, major companies are ... and local governments setting future mandates for renewable energy ... as an option. , Solara Power is a new ... several incentive programs available that allow qualifying homeowners to ...
Breaking Biology Technology:Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Mapi expands Pharmacovigilance and Risk Management capabilities 2Mapi expands Pharmacovigilance and Risk Management capabilities 3Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2Solara Power Announces Residential Solar Power with No Up-Front Fees 2
... 5 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... the extracellular matrix, today announced that David,Ramsay, Halozyme,s ... two investor conferences in February. Mr. Ramsay will ... candidates and 2008 milestones at,each conference., ...
... SHANGHAI, China, Feb. 5 /Xinhua-PRNewswire/ -- China-Biotics, ... a leading Chinese,firm specializing in the manufacture, ... today announced the third quarter,fiscal 2008 earnings ... 2008, will be held at 9 a.m. ...
... MISSISSAUGA, ON, Feb. 5 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: ... the research and,commercial development of technologies targeting the ... that,Chris Waddick, President and CEO, will present a ... the Waldorf Astoria, New York City, at 11:00,a.m. ...
Cached Biology Technology:Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference 2China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results 2China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results 3Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 3
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... , March 12, 2015 ... a standardized identity and access management (IAM) solution ... implementation schedule. With Beta System,s new IAM package, ... best practices gleaned from multiple IAM implementations across ... the software as well as any necessary services ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... sun ?for plants as well as people ?can be ... equivalent of "lobster tans," plants have developed an intricate ... to ward off the sun's harmful rays. , "We ... of photoprotection, but the question has been, how does ...
... genetically modified cassava plants produced roots that were more ... , The findings could help ease hunger in many ... (Manihot esculenta) as a primary food source, said Richard ... plant cellular and molecular biology at Ohio State University. ...
... characterized by a decrease in bone mass and density ... and deformities, afflicts some 10 million Americans over the ... Public Health (HSPH) have discovered that eliminating a protein, ... bone mass throughout their skeletal system. The results may ...
Cached Biology News:How plants avoid feeling the burn 2How plants avoid feeling the burn 3How plants avoid feeling the burn 4Super-sized cassava plants may help fight hunger in Africa 2Research identifies protein in mice that regulates bone formation 2
Contact us for more information...
Mol wt: average mol wt16,951.27 Da by calculation...
... the only PCR system that ensures successful ... It provides accuracy, consistency, and dependability for ... property of the DNA templates. This system ... unique blend of thermostable enzymes that is ...
... C2C12 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
Biology Products: